Thyroid Cancer Trial, Recruiting NCT05604963 Sponsor: University College, London Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT05604963
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you have already had your whole thyroid removed (Group 1):

  • You are aged 16 or older
  • You have been diagnosed with papillary thyroid cancer (PTC) where the tumour was between 1cm and 4cm, regardless of genetic markers found in the tumour
  • Your surgeon was able to remove all visible cancer during the operation
  • The cancer had not spread to lymph nodes, or had only spread to a small number of nearby lymph nodes (5 or fewer) with no spread beyond the lymph node itself
  • The cancer was either fully contained within the thyroid or had only just started to grow slightly beyond it
  • The cancer does not show certain higher-risk patterns under the microscope (small amounts may be acceptable — confirm with trial site)
  • There is no sign the cancer has grown into blood vessels (small microscopic involvement of tiny vessels may still be acceptable — confirm with trial site)
  • You have a specific type called encapsulated follicular variant PTC, where the cancer has only broken through its surrounding capsule
  • You have a very small papillary thyroid cancer (1cm or less) that is either found in multiple spots, or has spread to a small number of nearby lymph nodes (5 or fewer, with no spread beyond the lymph node)
  • You have been diagnosed with follicular thyroid cancer (including oncocytic or Hürthle cell type), where the tumour was between 1cm and 4cm, regardless of genetic markers
  • Your follicular thyroid cancer is the minimally invasive type, with capsule involvement and/or a small amount of blood vessel involvement (4 or fewer spots), and is contained within or just beyond the thyroid

If you have not yet had thyroid surgery (Group 2):

  • You are aged 16 or older
  • A biopsy or needle test has shown a low-risk differentiated thyroid cancer
  • The tumour appears to be between 1cm and 4cm based on scans, regardless of genetic markers
  • There is no sign the cancer has spread to nearby lymph nodes
  • The other side of your thyroid does not have any suspicious nodules, or any nodules found there have been assessed and appear non-concerning

Who may not be able to join:

If you have already had your whole thyroid removed (Group 1):

  • Your tumour was larger than 4cm
  • You have a single very small tumour (1cm or less) with no lymph node involvement
  • You have been diagnosed with NIFTP (a borderline condition that is not considered true cancer)
  • You have anaplastic, poorly differentiated, or medullary thyroid cancer
  • There was cancer left behind that the surgeon could visibly see after the operation
  • The cancer had grown extensively outside the thyroid gland
  • The cancer is classified as stage T4, or has visibly invaded surrounding tissues or structures
  • Cancer spread to nearby lymph nodes involved more than 5 lymph node spots, or had spread beyond the lymph node itself
  • Cancer has spread to lymph nodes further away from the thyroid
  • The cancer has spread to other parts of the body (for example, lungs or bones)
  • Your papillary thyroid cancer shows any of these higher-risk features: widely invasive growth, poorly differentiated cells, anaplastic cells, or is mainly made up of higher-risk cell types (such as tall cell, columnar cell, hobnail, or diffuse sclerosing)
  • Your follicular thyroid cancer (including oncocytic or Hürthle cell type) shows any of these features: extensive blood vessel invasion (more than 4 spots), widely invasive growth, poorly differentiated cells, or anaplastic cells

If you have not yet had thyroid surgery (Group 2):

  • The cancer has already spread to other parts of the body (for example, lungs or bones)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dae Kim, The Royal Marsden Hospital

Phone: 020 3108 4875

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 February 2022
Est. completion
31 July 2028

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

3 Year Recurrence Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov